Table 3 Characteristics of bispecific antibodies generated for AML
From: Acute myeloid leukemia targets for bispecific antibodies
MW (kDa) | Affinity(KD) n m | EC 50 p m | Clone | |||
|---|---|---|---|---|---|---|
Effector (CD3 and so on) | Target (CD33 and so on) | |||||
Parent clone | Bispecific format | |||||
CD33 × CD3 BiTE AMG 330(ref.9) | 55 | 5.1 | — | 8 | 0.4–3 | — |
60 | — | 0.1 | 10–100 | 15 | DRB2 (CD33) | |
CD33 × CD16 chemically conjugated23 | — | — | — | — | — | 251 (CD33), 3G8 (CD16) |
55 | 20 (scFv) | — | — | — | NM3E2 (CD16) | |
CD33 × CD16 × CD33 sctb29 | 90 | 45.1±4.3 | — | 7.9±1.1 | 1.8–18 | K132 (CD33), 3G8 (CD16) |
CD33 × CD16 × CD19 sctb30 | 90 | 49±5.2 | — | CD33 (29±1.9) | 7.2±2 | K132 (CD33), 3G8 (CD16) |
CD123 × CD16 × CD33 sctb31 | 90 | 21.7±1.8 | — | CD33 (17.8±2.2), CD123 (18.8±0.9) | 21–118 | K132 (CD33), 3G8 (CD16), CD123 (from phage41) |
140 | 10 | 0.01–0.05 | 0.1 | 10 | 12F1 (CD123), UCHT1 (CD3) | |
CD3 × CD123 DART42 | 59 | 9±2.3 | — | 0.13±0.01 | 0.17 | 7G3 (CD123) |
CD123 × CD16 bsscFv41 | 60 | 49±5 | — | 4.5–101 | 211–364 | 3G8 (CD16), CD123 (from phage41) |
CD15 × CD64 chemically conjugated54 | — | — | — | — | — | PM81 (CD15), 32 (CD64) |
— | — | — | — | — | H22 (CD64), 251 (CD33) | |
CD16 × CD33 chemically conjugated23 | — | — | — | — | — | 3G8 (CD16), 251 (CD33) |
CD3 × CD33 modular re-targeting system19 | — | — | 0.1 | — | — | MT-301 (CD3), DRB2 (CD33) |
CD33 × CD3 BiFaba,68 | ~100 | — | 7 | Similar to their parental clones | 25–445 | Mutated hM195 (CD33), and UCHT1 (CD3) |
anti-CD3 Fab′ × anti-CD13 Fab′ chemically conjugated51 | 100–110 | — | — | — | — | OKT3 (CD3), My7 (CD13) |
CD30 × CD16A TandAb60 | 105–110 | 0.39 | 17.2 | 9.3 | 35 800 | LSIV21 (CD16), HRS-3 (CD30) |
CD30 × CD16A bispecific diabody60 | 60 | 35 | 17.2 | 751 | 194 700 | LSIV21 (CD16), HRS-3 (CD30) |
— | — | — | 0.2 | — | ESK1 (WT1), L2K (CD3) | |
CD20 × CD47 DVD-Ig | — | — | CD47 (3.1) | — | 2B8 (CD20), B6H12.2 (CD47) | |
CLL1 × CD3 BiFab a,68 | ~100 | — | 6.1 | Similar to their parental clones | 2.1–41 | Mutated 1075.7 (CLL1), and UCHT1 (CD3) |
FLT-3 × CD3 BiTE71 | — | — | — | — | — | 4G8 (FLT-3),UCHT1 (CD3) |
FLT-3 × CD3 Fabsc71 | 87 | — | — | — | — | 4G8 (FLT-3), BV10 (FLT-3), UCHT1 (CD3), OKT3 (CD3), BMA031 (CD3) |
— | — | Bevacizumab (<0.1) Ang-2 (0.2) | Bevacizumab (<0.1) Ang-2 (0.2) | — | Bevacizumab=humanized A.4.6.1 (VEGF) and LC06 (Ang-2) | |
